Cancer J. 2010 May-Jun;16(3):262-72
Authors: Wilson PM, Labonte MJ, Lenz HJ
Although significant progress has been made in colorectal cancer (CRC) treatment within the last decade with the approval of multiple new agents, the prognosis for patients with metastatic CRC remains poor with 5-year survival rates of approximately 8%.
Graefes Arch Clin Exp Ophthalmol. 2010 Aug;248(8):1057-61
Authors: Shastry BS
BACKGROUND: Individual variation in drug response and adverse drug reactions are a serious problem in medicine. This inter-individual variation in drug response could be due to multiple factors such as disease determinants, environmental and genetic factors.
Protein Sci. 2010 Aug 26;
Authors: Kelly L, Fukushima H, Karchin R, Gow JM, Chinn LW, Pieper U, Segal MR, Kroetz DL, Sali A
The human ATP-binding cassette (ABC) transporter superfamily consists of 48 integral membrane proteins that couple the action of ATP binding and hydrolysis to the transport of diverse substrates across cellular membranes.
Psychiatr Danub. 2010 Jun;22(2):335-7
Authors: MihaljeviÄ-Peles A, Sagud M, Bozina N, ZivkoviÄ M, JovanoviÄ N
The concept of personalized drug therapy on the basis of genetic investigations has become a major issue in psychopharmacology. Pharmacogenetic studies have focused on polymorphisms in liver cytochrome P450 isoenzymes that metabolize many antidepressant and antipsychotic medications.
Kardiol Pol. 2005 Oct;63(4 Suppl 2):S440-9
Authors: Kozieradzka A, KamiÅski K, MusiaÅ WJ
The number of patients suffering from heart failure is constantly increasing. One of its main causes is coronary artery disease, especially myocardial infarction. Progression of heart failure depends both on the extent of ischaemic injury and the course of subsequent adaptive processes.
Future Oncol. 2010 Apr;6(4):563-85
Authors: RamÃrez J, Ratain MJ, Innocenti F
Pharmacogenetics aims to elucidate how genetic variation affects the efficacy and side effects of drugs, with the ultimate goal of personalizing medicine.
Pharmacogenomics J. 2010 Jun;10(3):191-9
Authors: Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, Liewehr DJ, Dahut WL, Miao X, Figg WD
The anticancer agent docetaxel shows significant inter-individual variation in its pharmacokinetic and toxicity profile. Thalidomide is an active anticancer agent and also shows wide pharmacological variation.